- Standigm Inc., a Seoul, South Korea-based Artificial Intelligence (AI) company for drug discovery, closed a $44.5m pre-IPO funding round
- The closing marks the last round of funding before the company goes to its planned initial public offering (IPO) on the Korea Exchange (KRX) later this year
- Standigm intends to use the funds to bolster business-to-business sales through its advanced platform technology
- Founded in 2015 and led by Jinhan Kim, CEO, Standigm is an AI-driven drug discovery company
- It provides AI platforms that range from new drug target discovery to novel drug lead generation, enabling pharmaceutical companies to save time and cost
- Standigm and its collaborator, SK holdings C&C opened iCLUE&ASK™, an AI-based drug target identification platform, to the public last September
